In the Phase 1b intratumoral study, 22 patients with cutaneous carcinomas were treated across five dose-escalation cohorts. PH-762 demonstrated no dose-limiting toxicities or serious adverse events, achieving a 65% pathological response rate overall and an 85% rate in the highest-dose cohort. Phio entered into a cGMP drug product manufacturing services agreement with a U.S. partner to supply its lead INTASYL® siRNA candidate, PH-762, for upcoming clinical trials and eventual commercial launch. This partnership secures production capacity and strategic advantages of a domestic supplier, supporting scale-up and regulatory compliance. Phio reports cash and equivalents sufficient to fund operations into the first half of 2027. The company targets FDA engagement in Q2 2026 to discuss next-stage clinical development plans for PH-762, aiming to advance into pivotal trials.